Back to top
more

Biohaven Ltd. (BHVN)

(Delayed Data from NYSE)

$13.57 USD

13.57
6,458,473

-0.05 (-0.37%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $13.56 -0.01 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Will Cigna (CI) Maintain Its Beat Streak in Q3 Earnings?

by Zacks Equity Research

Cigna's (CI) Q3 results are likely to reflect revenue growth owing to a strong fundamental performance. Earnings, however, might have been affected by steep medical costs from moderation in deferment of care related to the COVID-19 pandemic.

Kinjel Shah headshot

5 Drug/Biotech Stocks Set to Outpace Q3 Earnings Estimates

by Kinjel Shah

Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.

Zacks Equity Research

FDA Accepts Biohaven's (BHVN) sNDA for Migraine Drug Nurtec

by Zacks Equity Research

Biohaven (BHVN) is seeking the label expansion of its migraine drug Nurtec ODT as a preventive treatment of migraine.

Zacks Equity Research

Biohaven (BHVN) Q2 Earnings Beat on Strong Nurtec Uptake

by Zacks Equity Research

Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, demonstrates strong launch uptake.

Zacks Equity Research

Why Biohaven (BHVN) Might Surprise This Earnings Season

by Zacks Equity Research

Biohaven (BHVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Biotech Stock Roundup: GILD to Buy Forty Seven, Pipeline Updates From BIIB & More

by Zacks Equity Research

The biotech sector was in focus with new drug approvals, acquisitions and regular pipeline updates from quite a few companies.

Zacks Equity Research

Options Traders Expect Huge Moves in Biohaven Pharmaceutical (BHVN) Stock

by Zacks Equity Research

Investors need to pay close attention to Biohaven Pharmaceutical (BHVN) stock based on the movements in the options market lately.

Zacks Equity Research

Options Traders Expect Huge Moves in Biohaven (BHVN) Stock

by Zacks Equity Research

Investors need to pay close attention to Biohaven (BHVN) stock based on the movements in the options market lately.

Zacks Equity Research

Options Traders Expect Huge Moves in Biohaven Pharmaceutical (BHVN) Stock

by Zacks Equity Research

Biohaven Pharmaceutical (BHVN) needs investors to pay close attention to the stock based on moves in the options market lately.

Zacks Equity Research

Implied Volatility Surging for Biohaven Pharmaceutical (BHVN) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Biohaven Pharmaceutical (BHVN) stock based on the movements in the options market lately.